Immunologic and genetic markers in patients with idiopathic ocular inflammation and a family history of inflammatory bowel disease

Javaneh Abbasian; Tammy M. Martin; Sarju Patel; Howard H. Tessler; Debra A. Goldstein

doi:10.1016/j.ajo.2012.01.016

Immunologic and genetic markers in patients with idiopathic ocular inflammation and a family history of inflammatory bowel disease

Javaneh Abbasian
, Tammy M. Martin
, Sarju Patel
, Howard H. Tessler
, Debra A. Goldstein

Ophthalmology

Research output: Contribution to journal › Article › peer-review

11 Scopus citations

Abstract

• PURPOSE: To evaluate the prevalence of immunologic and genetic markers in patients with idiopathic ocular inflammation and a family history of inflammatory bowel disease. • DESIGN: Matched case-control study. • METHODS: Patients with a diagnosis of idiopathic ocular inflammation and family history of inflammatory bowel disease who did not have inflammatory bowel disease themselves were identified and matched to control patients with idiopathic ocular inflammation. Serum was evaluated for immunologic markers using Prometheus IBD Serology 7. Genomic DNA was analyzed for single nucleotide polymorphisms (SNP) of the NOD2 gene associated with Crohn disease. • RESULTS: Fifteen patients with idiopathic ocular inflammation and family history of inflammatory bowel disease were matched to 15 control patients based on age, sex, and race. Eight of 15 patients (53%) with a family history of inflammatory bowel disease had elevated p-ANCA antibody levels compared to 3 of 15 controls (20%) (1-sided P = .04) with a matched analysis odds ratio of 6.0 (1-sided P = .06). Four of 15 patients (27%) with family history of inflammatory bowel disease tested positive for immunologic markers predicting ulcerative colitis, while no control patients tested positive (1-sided P = .06). Carrier rates of NOD2 SNPs did not differ significantly between the test and control groups. • CONCLUSIONS: One-quarter of patients with idiopathic ocular inflammation and a family history of inflammatory bowel disease had immunologic markers predicting bowel disease, and one-half had elevated p-ANCA levels. Prometheus IBD Serology 7 may be useful in the evaluation of selected patients with unexplained uveitis.

Original language	English (US)
Pages (from-to)	72-77
Number of pages	6
Journal	American journal of ophthalmology
Volume	154
Issue number	1
DOIs	https://doi.org/10.1016/j.ajo.2012.01.016
State	Published - Jul 2012

Funding

All authors have completed and submitted the ICMJE Form for Disclosure of Potential Conflicts of Interest. Publication of this article was supported in part by a grant from the Illinois Society for the Prevention of Blindness (Chicago, Illinois) awards to Dr Abbasian and Dr Goldstein; as well the National Institutes of Health (NEI, EY013139 ; Bethesda, Maryland) and the Research to Prevent Blindness (New York, New York) awards to Dr Martin and the Casey Eye Institute. Involved in design of the study (D.G., J.A.), data collection (J.A.), management (J.A.), statistics (S.P.), analysis (D.G., J.A., T.M., H.T., S.P.), and preparation, review, and approval of the manuscript (D.G., J.A., T.M., H.T., S.P.). Approval for a prospective study involving patients with idiopathic ocular inflammation and a family history of inflammatory bowel disease was obtained from the Institutional Review Boards (IRB) at both the University of Illinois at Chicago and Oregon Health & Science University and was in accordance with HIPAA regulations. The authors also thank the following research personnel from Oregon Health & Sciences University: Kelley Goodwin and Trudy Doyle for expert technical assistance with NOD2 SNP genotyping, and Carrie Austin for study coordination between the 2 centers.

Funders	Funder number
National Eye Institute and Casey Eye Institute
Illinois Society for the Prevention of Blindness
Author National Institutes of Health National Institutes of Health National Institutes of Health National Institutes of Health The Bev Hartig Huntington's Disease Foundation National Institutes of Health
National Eye Institute and Casey Eye Institute	R01EY013139
Research to Prevent Blindness

ASJC Scopus subject areas

Ophthalmology

Access to Document

10.1016/j.ajo.2012.01.016

Cite this

@article{799bf1f432514008af1acd03d2cf6ca8,

title = "Immunologic and genetic markers in patients with idiopathic ocular inflammation and a family history of inflammatory bowel disease",

abstract = "• PURPOSE: To evaluate the prevalence of immunologic and genetic markers in patients with idiopathic ocular inflammation and a family history of inflammatory bowel disease. • DESIGN: Matched case-control study. • METHODS: Patients with a diagnosis of idiopathic ocular inflammation and family history of inflammatory bowel disease who did not have inflammatory bowel disease themselves were identified and matched to control patients with idiopathic ocular inflammation. Serum was evaluated for immunologic markers using Prometheus IBD Serology 7. Genomic DNA was analyzed for single nucleotide polymorphisms (SNP) of the NOD2 gene associated with Crohn disease. • RESULTS: Fifteen patients with idiopathic ocular inflammation and family history of inflammatory bowel disease were matched to 15 control patients based on age, sex, and race. Eight of 15 patients (53\%) with a family history of inflammatory bowel disease had elevated p-ANCA antibody levels compared to 3 of 15 controls (20\%) (1-sided P = .04) with a matched analysis odds ratio of 6.0 (1-sided P = .06). Four of 15 patients (27\%) with family history of inflammatory bowel disease tested positive for immunologic markers predicting ulcerative colitis, while no control patients tested positive (1-sided P = .06). Carrier rates of NOD2 SNPs did not differ significantly between the test and control groups. • CONCLUSIONS: One-quarter of patients with idiopathic ocular inflammation and a family history of inflammatory bowel disease had immunologic markers predicting bowel disease, and one-half had elevated p-ANCA levels. Prometheus IBD Serology 7 may be useful in the evaluation of selected patients with unexplained uveitis.",

author = "Javaneh Abbasian and Martin, \{Tammy M.\} and Sarju Patel and Tessler, \{Howard H.\} and Goldstein, \{Debra A.\}",

note = "Funding Information: All authors have completed and submitted the ICMJE Form for Disclosure of Potential Conflicts of Interest. Publication of this article was supported in part by a grant from the Illinois Society for the Prevention of Blindness (Chicago, Illinois) awards to Dr Abbasian and Dr Goldstein; as well the National Institutes of Health (NEI, EY013139 ; Bethesda, Maryland) and the Research to Prevent Blindness (New York, New York) awards to Dr Martin and the Casey Eye Institute. Involved in design of the study (D.G., J.A.), data collection (J.A.), management (J.A.), statistics (S.P.), analysis (D.G., J.A., T.M., H.T., S.P.), and preparation, review, and approval of the manuscript (D.G., J.A., T.M., H.T., S.P.). Approval for a prospective study involving patients with idiopathic ocular inflammation and a family history of inflammatory bowel disease was obtained from the Institutional Review Boards (IRB) at both the University of Illinois at Chicago and Oregon Health \& Science University and was in accordance with HIPAA regulations. The authors also thank the following research personnel from Oregon Health \& Sciences University: Kelley Goodwin and Trudy Doyle for expert technical assistance with NOD2 SNP genotyping, and Carrie Austin for study coordination between the 2 centers.",

year = "2012",

month = jul,

doi = "10.1016/j.ajo.2012.01.016",

language = "English (US)",

volume = "154",

pages = "72--77",

journal = "American journal of ophthalmology",

issn = "0002-9394",

publisher = "Elsevier Inc.",

number = "1",

}

TY - JOUR

T1 - Immunologic and genetic markers in patients with idiopathic ocular inflammation and a family history of inflammatory bowel disease

AU - Abbasian, Javaneh

AU - Martin, Tammy M.

AU - Patel, Sarju

AU - Tessler, Howard H.

AU - Goldstein, Debra A.

N1 - Funding Information: All authors have completed and submitted the ICMJE Form for Disclosure of Potential Conflicts of Interest. Publication of this article was supported in part by a grant from the Illinois Society for the Prevention of Blindness (Chicago, Illinois) awards to Dr Abbasian and Dr Goldstein; as well the National Institutes of Health (NEI, EY013139 ; Bethesda, Maryland) and the Research to Prevent Blindness (New York, New York) awards to Dr Martin and the Casey Eye Institute. Involved in design of the study (D.G., J.A.), data collection (J.A.), management (J.A.), statistics (S.P.), analysis (D.G., J.A., T.M., H.T., S.P.), and preparation, review, and approval of the manuscript (D.G., J.A., T.M., H.T., S.P.). Approval for a prospective study involving patients with idiopathic ocular inflammation and a family history of inflammatory bowel disease was obtained from the Institutional Review Boards (IRB) at both the University of Illinois at Chicago and Oregon Health & Science University and was in accordance with HIPAA regulations. The authors also thank the following research personnel from Oregon Health & Sciences University: Kelley Goodwin and Trudy Doyle for expert technical assistance with NOD2 SNP genotyping, and Carrie Austin for study coordination between the 2 centers.

PY - 2012/7

Y1 - 2012/7

N2 - • PURPOSE: To evaluate the prevalence of immunologic and genetic markers in patients with idiopathic ocular inflammation and a family history of inflammatory bowel disease. • DESIGN: Matched case-control study. • METHODS: Patients with a diagnosis of idiopathic ocular inflammation and family history of inflammatory bowel disease who did not have inflammatory bowel disease themselves were identified and matched to control patients with idiopathic ocular inflammation. Serum was evaluated for immunologic markers using Prometheus IBD Serology 7. Genomic DNA was analyzed for single nucleotide polymorphisms (SNP) of the NOD2 gene associated with Crohn disease. • RESULTS: Fifteen patients with idiopathic ocular inflammation and family history of inflammatory bowel disease were matched to 15 control patients based on age, sex, and race. Eight of 15 patients (53%) with a family history of inflammatory bowel disease had elevated p-ANCA antibody levels compared to 3 of 15 controls (20%) (1-sided P = .04) with a matched analysis odds ratio of 6.0 (1-sided P = .06). Four of 15 patients (27%) with family history of inflammatory bowel disease tested positive for immunologic markers predicting ulcerative colitis, while no control patients tested positive (1-sided P = .06). Carrier rates of NOD2 SNPs did not differ significantly between the test and control groups. • CONCLUSIONS: One-quarter of patients with idiopathic ocular inflammation and a family history of inflammatory bowel disease had immunologic markers predicting bowel disease, and one-half had elevated p-ANCA levels. Prometheus IBD Serology 7 may be useful in the evaluation of selected patients with unexplained uveitis.

AB - • PURPOSE: To evaluate the prevalence of immunologic and genetic markers in patients with idiopathic ocular inflammation and a family history of inflammatory bowel disease. • DESIGN: Matched case-control study. • METHODS: Patients with a diagnosis of idiopathic ocular inflammation and family history of inflammatory bowel disease who did not have inflammatory bowel disease themselves were identified and matched to control patients with idiopathic ocular inflammation. Serum was evaluated for immunologic markers using Prometheus IBD Serology 7. Genomic DNA was analyzed for single nucleotide polymorphisms (SNP) of the NOD2 gene associated with Crohn disease. • RESULTS: Fifteen patients with idiopathic ocular inflammation and family history of inflammatory bowel disease were matched to 15 control patients based on age, sex, and race. Eight of 15 patients (53%) with a family history of inflammatory bowel disease had elevated p-ANCA antibody levels compared to 3 of 15 controls (20%) (1-sided P = .04) with a matched analysis odds ratio of 6.0 (1-sided P = .06). Four of 15 patients (27%) with family history of inflammatory bowel disease tested positive for immunologic markers predicting ulcerative colitis, while no control patients tested positive (1-sided P = .06). Carrier rates of NOD2 SNPs did not differ significantly between the test and control groups. • CONCLUSIONS: One-quarter of patients with idiopathic ocular inflammation and a family history of inflammatory bowel disease had immunologic markers predicting bowel disease, and one-half had elevated p-ANCA levels. Prometheus IBD Serology 7 may be useful in the evaluation of selected patients with unexplained uveitis.

UR - https://www.scopus.com/pages/publications/84862771313

UR - https://www.scopus.com/pages/publications/84862771313#tab=citedBy

U2 - 10.1016/j.ajo.2012.01.016

DO - 10.1016/j.ajo.2012.01.016

M3 - Article

C2 - 22464367

AN - SCOPUS:84862771313

SN - 0002-9394

VL - 154

SP - 72

EP - 77

JO - American journal of ophthalmology

JF - American journal of ophthalmology

IS - 1

ER -

Immunologic and genetic markers in patients with idiopathic ocular inflammation and a family history of inflammatory bowel disease

Abstract

Funding

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this